Maiwald Intellectual Property

Wilhelm Eger of Maiwald Intellectual Property examines how the Pemetrexed case has influenced European approaches to patent infringement under the doctrine of equivalency and how numbers and measurements are addressed

German courts are now permitting the service of claims on Chinese respondents by publication to ensure effective legal protection. Marco Stief of Maiwald contrasts this approach with the Unified Patent Court’s stricter stance

Christian Meyer and Gisela Grabow of Maiwald explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster competition and enhance patient access

Christian Meyer and Gisela Grabow of Maiwald consider proposals under the European Commission’s Action Plan for Intellectual Property that aim to simplify extended protection for medicinal products through a unitary supplementary protection certificate

Christian Meyer and Gisela Grabow of Maiwald discuss potential changes to the EU pharmaceutical regulation and their potential impact on data and market protection timelines for medicinal products

Michaela Weigel-Krusemarck of Maiwald considers the impact of the Enlarged Board of Appeal introducing a rebuttable presumption that a patent applicant is entitled to claim priority